DLB Stock Recent News

Dolby Laboratories (DLB -6.84%), a globally recognized leader in audio and visual technology, reported earnings for Q3 FY2025 on July 31, 2025. The company posted GAAP revenue of $315.5 million, ahead of the analyst consensus of $305.2 million (GAAP) and up from $288.8 million (GAAP) in Q3 FY2024.

DLB beats Q3 earnings and revenue estimates as Dolby Atmos and Dolby Vision gain ground across devices and content.

Dolby Laboratories, Inc. (NYSE:DLB ) Q3 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Kevin J. Yeaman - President, CEO & Director Peter L.

Although the revenue and EPS for Dolby Laboratories (DLB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Dolby Laboratories (DLB) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.71 per share a year ago.

SAN FRANCISCO , July 31, 2025 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the third quarter of fiscal 2025. "We had solid results in Q3 and we continue to see strong engagement with creators, distributors and device manufacturers," said Kevin Yeaman, President and CEO, Dolby Laboratories.

- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo -

Dolby Laboratories, Inc. is now attractively valued, with a forward P/E below 20x and a 1.77% dividend yield, making it a compelling buy. Earnings have improved significantly, and the company's licensing model ensures steady revenue across diverse industries, supporting long-term growth. Despite historic underperformance versus the S&P 500, current valuation offers 15-22% annual upside with limited downside risk.

SAN FRANCISCO , July 8, 2025 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, will release financial results for the third quarter (Q3) fiscal year 2025 after the close of regular trading on Thursday, July 31, 2025. Members of Dolby management will lead a conference call open to all interested parties to discuss Q3 fiscal year 2025 financial results for Dolby Laboratories at 2:00 p.m.

- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer's Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company will conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025.